|
Real-time Estimate
Cboe BZX
22:20:18 24/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 2.395 USD | +0.63% |
|
+4.37% | +32.78% |
| 08-12 | Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 | |
| 08-12 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
ETFs positioned on Protalix BioTherapeutics, Inc.
| Name | YTD change | Weight | AuM | |
|---|---|---|---|---|
 | +24.71% | 0.03% | 1,518 M€ | |
| 0.00% | 0.02% | 53 M€ | |
| +18.68% | 0.01% | 1,568 M€ | |
| +20.27% | 0.01% | 3,050 M€ | |
| +18.72% | 0.01% | 15,028 M€ | |
| +12.50% | 0.01% | 18 M€ | |
| +19.57% | 0.01% | 520 M€ | |
| +23.69% | 0.01% | 14,676 M€ | |
| +11.77% | 0% | 9 M€ | |
| +20.75% | 0% | 1,540 M€ | |
| +21.09% | 0% | 82,179 M€ | |
| +6.01% | 0% | 1,395 M€ | |
| +12.55% | 0% | 4,863 M€ | |
| +16.61% | 0% | 19 M€ | |
| +14.53% | 0% | 29 M€ | |
| +14.23% | 0% | 60 M€ | |
| +14.48% | 0% | 41 M€ | |
| +8.74% | 0% | 162 M€ | |
| +13.61% | 0% | 88 M€ | |
| 0.00% | 0% | 43 M€ | |
| +12.37% | 0% | 91 M€ | |
| +14.39% | 0% | 16 M€ | |
| +10.78% | 0% | 110 M€ | |
| +9.04% | 0% | 113 M€ | |
| +16.42% | 0% | 7 M€ | |
| +6.08% | 0% | 43 M€ | |
| +12.11% | 0% | 194 M€ | |
| +14.66% | 0% | 62 M€ | |
| +10.59% | 0% | 513 M€ | |
| +8.23% | 0% | 20 M€ | |
| -5.87% | -.--% | 538 M€ |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PLX Stock
- ETFs Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
